Cargando…

Treatment and survival analyses of completely resected thymic carcinoma patients

PURPOSE: To investigate the impact of chemotherapy and/or radiotherapy on disease-free survival (DFS) and overall survival (OS) rates of patients with thymic carcinoma after complete resection. METHODS: Between 2001 and 2013, 54 patients with complete resection of thymic carcinoma in Hangzhou Cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Yanjiao, Wu, Shixiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574812/
https://www.ncbi.nlm.nih.gov/pubmed/26392777
http://dx.doi.org/10.2147/OTT.S87222
_version_ 1782390680706875392
author Mao, Yanjiao
Wu, Shixiu
author_facet Mao, Yanjiao
Wu, Shixiu
author_sort Mao, Yanjiao
collection PubMed
description PURPOSE: To investigate the impact of chemotherapy and/or radiotherapy on disease-free survival (DFS) and overall survival (OS) rates of patients with thymic carcinoma after complete resection. METHODS: Between 2001 and 2013, 54 patients with complete resection of thymic carcinoma in Hangzhou Cancer Hospital were retrospectively reviewed. The Kaplan–Meier method was used to evaluate the survival rates. The Cox proportional hazard model was used for multivariate analysis. RESULTS: Among the 54 patients, Masaoka stage I was observed in seven patients, II in 22 patients, and III in 25 patients. Sixteen patients received adjuvant chemotherapy (six with chemotherapy alone and ten with radiotherapy and chemotherapy), 25 patients received adjuvant radiotherapy, and 13 patients did not receive radiotherapy and/or chemotherapy. The 5-year DFS and OS rates for all patients were 63.0% and 73.4%, respectively. Univariate analysis revealed that radiotherapy was significantly associated with DFS and OS (P=0.014 and P=0.029, respectively), while adjuvant chemotherapy was not (P=0.122 and P=0.373, respectively). Multivariate analysis showed that adjuvant radiotherapy increased DFS (P=0.041), but not OS (P=0.051). CONCLUSION: Complete resection followed by adjuvant radiotherapy increased disease-free rates of thymic carcinoma patients.
format Online
Article
Text
id pubmed-4574812
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45748122015-09-21 Treatment and survival analyses of completely resected thymic carcinoma patients Mao, Yanjiao Wu, Shixiu Onco Targets Ther Original Research PURPOSE: To investigate the impact of chemotherapy and/or radiotherapy on disease-free survival (DFS) and overall survival (OS) rates of patients with thymic carcinoma after complete resection. METHODS: Between 2001 and 2013, 54 patients with complete resection of thymic carcinoma in Hangzhou Cancer Hospital were retrospectively reviewed. The Kaplan–Meier method was used to evaluate the survival rates. The Cox proportional hazard model was used for multivariate analysis. RESULTS: Among the 54 patients, Masaoka stage I was observed in seven patients, II in 22 patients, and III in 25 patients. Sixteen patients received adjuvant chemotherapy (six with chemotherapy alone and ten with radiotherapy and chemotherapy), 25 patients received adjuvant radiotherapy, and 13 patients did not receive radiotherapy and/or chemotherapy. The 5-year DFS and OS rates for all patients were 63.0% and 73.4%, respectively. Univariate analysis revealed that radiotherapy was significantly associated with DFS and OS (P=0.014 and P=0.029, respectively), while adjuvant chemotherapy was not (P=0.122 and P=0.373, respectively). Multivariate analysis showed that adjuvant radiotherapy increased DFS (P=0.041), but not OS (P=0.051). CONCLUSION: Complete resection followed by adjuvant radiotherapy increased disease-free rates of thymic carcinoma patients. Dove Medical Press 2015-09-09 /pmc/articles/PMC4574812/ /pubmed/26392777 http://dx.doi.org/10.2147/OTT.S87222 Text en © 2015 Mao and Wu. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Mao, Yanjiao
Wu, Shixiu
Treatment and survival analyses of completely resected thymic carcinoma patients
title Treatment and survival analyses of completely resected thymic carcinoma patients
title_full Treatment and survival analyses of completely resected thymic carcinoma patients
title_fullStr Treatment and survival analyses of completely resected thymic carcinoma patients
title_full_unstemmed Treatment and survival analyses of completely resected thymic carcinoma patients
title_short Treatment and survival analyses of completely resected thymic carcinoma patients
title_sort treatment and survival analyses of completely resected thymic carcinoma patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574812/
https://www.ncbi.nlm.nih.gov/pubmed/26392777
http://dx.doi.org/10.2147/OTT.S87222
work_keys_str_mv AT maoyanjiao treatmentandsurvivalanalysesofcompletelyresectedthymiccarcinomapatients
AT wushixiu treatmentandsurvivalanalysesofcompletelyresectedthymiccarcinomapatients